Assessment of clinical and analytical performance characteristics of an HPV genotyping test

Diagnostic Cytopathology

Volumn 40, Issue 4, 2012, Pages 367-373

  Schutzbank, Ted E ^a   Ginocchio, Christine C ^b  

^a Labcorp Drug Development   (United States)

^b Northwell Health   (United States)

Author keywords

cervical cancer; genotyping; high risk; HPV; laboratory practices

Indexed keywords

DNA;

ACCURACY; CLINICAL ASSESSMENT; CROSS REACTION; GENOTYPE; HUMAN; NONHUMAN; PERFORMANCE; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SENSITIVITY ANALYSIS; STORAGE; VALIDATION PROCESS; WART VIRUS;

GENOTYPING TECHNIQUES; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REPRODUCIBILITY OF RESULTS;

EID: 84859107412     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21661     Document Type: Review

References (23)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Mcijer CJ, Munoz N,. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19. (Pubitemid 29406813)
2. Castle PE, Burk ACRRD, Herrero R, Wacholder S, Alfaro M, Morales J, Sherman DGME, Solomon D, Schiffman M,. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: Population based cohort study. BMJ 2009; 339: 2569.
3. Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS,. Persistent human papillomavirus infection and cervical neoplasia: A systematic review and meta-analysis. Am JEpidemiol 2008; 168: 123-137. (Pubitemid 351951589)
4. Trottier H, Franco EL,. The epidemiology of genital human papillomavirus infection. Vaccine 2006; 24: S1-S15.
5. Trottier H, Mahmud SM, Lindsay L, Jenkins D, Quint W, Wieting SL, Schuind A, Franco EL,; GSKIIPV-001 Vaccine Study Group. Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women. Cancer Epidemiol Biomarkers Prev 2009; 18: 854-862.
6. Wheeler CM, Hunt WC, Schiffman M, Castle PE,. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis 2006; 194: 1291-1299. (Pubitemid 44630975)
7. Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, Goldie SJ, Harper DM, Kinney W, Moscicki A-B, Noller KL, Wheeler CM, Ades T, Andrews KS, Doroshenk MK, Kahn KG, Schmidt C, Shafey O, Smith RA, Partridge EE, on behalf of (for The Gynecologic Cancer Advisory Group), Garcia F,. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007; 57: 7-28. (Pubitemid 46148088)
8. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T,. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095-1101. (Pubitemid 44116919)
9. Wright TC, Jr,. Chapter 3: Pathology of HPV infection at the cytologic and histologic levels: Basis for a 2-tiered morphologic classification system. Int J Gynecol Obstet 2006; 94: S22-S31. (Pubitemid 46175819)
10. Moscicki AB, Schiffman M, Kjaer S, Villa LL,. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine 2006; 24: S3/42-51.
11. Ostor AG,. Natural history of cervical intraepithelial neoplasia: A critical review. Int J Gynecol Pathol 1993; 12: 186-192. (Pubitemid 23095196)
12. Bulkmans NWJ, Bcrkhof J, Rozendaal L, van Kemenade FJ, Boeke AJP, Bulk S, Voorhorst FJ, Verheijen RHM, van Groningen K, Boon ME, Ruitinga W, van Ballegooijen M, Snijders PJF, Meijer CJLM., Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764-1772. (Pubitemid 350137476)
13. Mayrand M-H, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL, for the Canadian Cervical Cancer Screening Trial Study Croup. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579-1588. (Pubitemid 47598400)
14. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rædberg T, Strander B, Johansson B, Forslund O, Hansson B-G, Rylander E, Dillner J,. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-1597. (Pubitemid 47598401)
15. Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, De Lillo M, Naldoni C, Pierotti P, Rizzolo R, Segnan N, Schineaglia P, Zorzi M, Confortini M, Cuzick J,; New Technologies for Cervical Cancer screening Working Group. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: Results at recruitment for a randomised controlled trial. Lancet Oncol 2006; 7: 547-555. (Pubitemid 43923665)
16. Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla Palma P, Del Mistro A, Folicaldi S, Gillio-Tos A, Nardo G, Naldoni C, Schincaglia P, Zorzi M, Confortini M, Cuzick J,; New Technologies for Cervical Cancer Working Group. Human papillomavirus testing and liquid-based cytology: Results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006; 98: 765-774. (Pubitemid 43983300)
17. Meijer CJ, Berkhof H, Heideman DA, Hesselink AT, Snijders PJ,. Validation of high-risk HPV tests for primary cervical screening. J Clin Virol 2009; 46: S1-S4.
18. ASCCP. HPV Genotyping Clinical Update. 2009; Available from:.
19. Seabrook JM, Hubbard RA,. Achieving quality reproducible results and maintaining compliance in molecular diagnostic testing of human papillomavirus. Arch Pathol Lab Med 2003; 127: 978-983. (Pubitemid 36994858)
20. FDA. Draft guidance for industry and FDA staff-Establishing the performance characteristics of in vitro diagnostic devices for the detection or detection and differentiation of human papillomaviruses. Accessed on June 10, 2010.
21. Wright TC, Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D, for the 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007; 197: 346-355. (Pubitemid 47464164)
22. Berkhof J, Bulkmans NWJ, Blecker MCG, Bulk S, Snijders PJF, Voorhorst FJ, Meijer CJLM,. Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol Biomarkers Prev 2006; 15: 1268-1273. (Pubitemid 44125280)
23. Khan MJ, Castle PE, Lorinez AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M,. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072-1079. (Pubitemid 41417924)